Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Short Interest Down 50.3% in April

Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) was the target of a significant decline in short interest during the month of April. As of April 15th, there was short interest totalling 14,800 shares, a decline of 50.3% from the March 31st total of 29,800 shares. Based on an average trading volume of 23,800 shares, the days-to-cover ratio is presently 0.6 days. Currently, 1.7% of the company’s stock are sold short.

Virpax Pharmaceuticals Stock Up 6.2 %

Shares of NASDAQ VRPX opened at $3.10 on Friday. Virpax Pharmaceuticals has a 1 year low of $2.40 and a 1 year high of $11.77. The stock’s 50-day simple moving average is $3.70 and its 200-day simple moving average is $4.44.

Virpax Pharmaceuticals Company Profile

Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.